The meta-analyses evaluated the effect of mono or combination PAH therapies on FC, 6-MWD, NT-proBNP level, PVR, RAP, and CI measured between 12 and 24 weeks and the risk of clinical worsening. The gene discussed is NPPB; the disease is pulmonary arterial hypertension.